Drug eluting stents in coronary arteries - early assessment briefs (Alert)
Swedish Council on Technology Assessment in Health Care
Record ID 32004000318
Swedish
Authors' objectives:
This review aims to assess the available evidence on drug eluting stents in coronary arteries.
Authors' recommendations:
There is strong scientific evidence that DES treatment - in comparison to BMS - reduces the risk for restenosis in the stent (Evidence grade 1). Followup lasting up to one year has shown that fewer repeat interventions have been performed in patients treated with DES in comparison to patients treated with BMS (Evidence grade 1). The extent to which this has affected patients symptoms, well being, or the use of medication has not been reported. Followup lasting up to one year provides no support for differences in risks of myocardial infarction or death between DES and BMS. Likewise, there is no support for differences in side effects and complications between DES and BMS.
Authors' methods:
Review
Details
Project Status:
Completed
URL for project:
http://www.sbu.se/Published
Year Published:
2004
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Sweden
MeSH Terms
- Coronary Disease
- Coronary Restenosis
- Heart Diseases
- Stents
Contact
Organisation Name:
Swedish Agency for Health Technology Assessment and Assessment of Social Services
Contact Address:
P.O. Box 3657, SE-103 59 Stockholm, Sweden. Tel: +46 8 4123200, Fax: +46 8 4113260
Contact Name:
registrator@sbu.se
Contact Email:
registrator@sbu.se
Copyright:
Swedish Council on Technology Assessment in Health Care (SBU)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.